Navigation Links
Progress Made in Predicting Breast Cancer Risk

Breast density, tumor characteristics help fine-tune treatment, study says

FRIDAY, Dec. 12 (HealthDay News) -- Researchers are making progress in predicting breast cancer risk, recurrence risk and response to cancer treatment by looking at such factors as breast density and tumor size, a panel of experts report.

The scientists presented their data during a teleconference Friday at the annual San Antonio Breast Cancer Symposium in Texas.

Patients with breast cancer tumors known as HER2-positive, even those a centimeter or less in diameter, have a substantially increased risk for relapse, and additional treatment after surgery should be considered, said Dr. Ana Gonzalez-Angulo, a researcher at the University of Texas M.D. Anderson Cancer Center.

Currently, guidelines call for no further treatment after surgery for these small cancers, but Gonzalez-Angulo said her findings suggest that thinking be reconsidered.

She evaluated 965 patients from M.D. Anderson Cancer Center, and validated the results with 350 European patients. All had small tumors, one centimeter in diameter or smaller, and 10 percent had HER2-positive tumors. HER2-positive breast cancer tests positive for a protein called human epidermal growth factor receptor 2, and these cancers tend to be more aggressive.

"The patients who had HER2-positive disease were the ones with the worst prognosis," she said. The five-year recurrence was 23 percent for those with HER-2 positive disease, compared to about 6 percent for those with HER-2 negative disease.

"We should start thinking about adjuvant therapy, as well as clinical trials," she said. "Twenty-three percent [recurrence] is very high."

The data show that even women with small cancers, under 1 centimeter, are at risk of recurrence, especially if the tumor is HER2-positive, said Dr. Claudine Isaacs, director of the clinical breast cancer program at Georgetown University Medical Center, in Washington, D.C.

There has been ongoing debate about how to treat these tumors, according to Isaacs. The new study, she said, "adds support to the notion to consider" further treatment.

In other findings reported at the meeting, changes in breast density during treatment with tamoxifen, a drug often used to lower breast cancer risk, can help predict how well the drug is working, said Jack Cuzick, head of the Cancer Research UK Centre for Epidemiology, Mathematics and Statistics in London.

He evaluated more than 7,000 participants involved in the International Breast Intervention Study I, assessing their breast density after 12 to 18 months of tamoxifen treatment or placebo treatment, then looking at breast cancer risk.

For the 46 percent of women in the tamoxifen arm whose density was reduced by 10 percent or greater, the risk of breast cancer declined by 52 percent compared to the control group getting placebo. The risk of breast cancer declined by just 8 percent in the 54 percent of women whose density was not reduced by 10 percent.

Breast density is easy and simple to measure on a mammogram, he said, and a useful predictor of breast cancer risk. Now, based on his findings, it's also a good predictor of response to tamoxifen.

Isaacs called that finding valuable. Being able to identify whether a woman is benefiting from the tamoxifen early will allow her physician to consider other treatments, she said.

More information

To learn more about cancer terms, visit the U.S. National Cancer Institute.

SOURCES: Dec. 12, 2008, teleconference with Ana M. Gonzalez-Angulo, M.D., researcher, University of Texas M.D. Anderson Cancer Center, Houston; Claudine Isaacs, M.D., director, clinical breast cancer program, and associate professor, medicine, Georgetown University Medical Center, Washington, D.C.; Jack Cuzick, Ph.D., head, Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, London

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
2. New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions
3. Aggressive Therapy May Stem CF Progression in Infants
4. Intervention in infants with cystic fibrosis key to slowing progression
5. Go Healthy Updates Progress With University Sports Programs
6. Report Shows Progress in Fight Against Cancer, but Congress, States Must Step Up Efforts to Reduce Smoking, Lung Cancer
7. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
8. Advanced lung cancer patients see improved, progression-free survival
9. EntreMed Reports Clinical Program Progress and Company Update
10. Alsius Corporation Reports Record Third Quarter 2008 Financial Results and Business Progress
11. Researchers find predictive tests and early treatment delay progression of blood cell cancer
Post Your Comments:
Related Image:
Progress Made in Predicting Breast Cancer Risk
(Date:11/27/2015)... ... November 27, 2015 , ... ... software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into ... Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that ...
(Date:11/26/2015)... ... , ... Inevitably when people think Thanksgiving, they also think Holiday sales and ... Friday and Cyber Monday massage chair sales to receive the best pricing ... to find the best massage chair deals, they can see all of the coupons ...
(Date:11/26/2015)... Ashburn, VA (PRWEB) , ... November 26, 2015 ... ... Planners, an American Express Travel Representative. As a franchise owner, Somu now offers ... range of cruise, destination wedding packages, private cruise sales, as well as, cabin ...
(Date:11/26/2015)... ... 26, 2015 , ... Jobs in hospital medical laboratories and in the imaging ... staffing agency Aureus Medical Group . These fields, as well as ... searching for healthcare jobs through the company’s website, , The leading ...
(Date:11/26/2015)... ... 26, 2015 , ... WorldCare International, Inc., the first company ... Employee Benefits Conference. The Employee Benefits Conference was hosted by the International Foundation ... 11th, 2015. The conference was held at the Hawaii Convention Center in Honolulu, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Therapeutic Drug Monitoring ... Forecasts, Competitive Intelligence, Emerging Opportunities"  report ... ) has announced the addition ...
Breaking Medicine Technology: